down during development and have an estimated half-life of ≈40 years. 11 In addition, there is a collagen deposition between the SMCs and the elastin lamellae. The proper construction of the elastic lamellae and collagen fibers is dependent on lysyl oxidases, which are extracellular copper enzymes that catalyze the formation of lysine-derived cross-links in elastin-and hydroxylysine-derived cross-links in collagens. Mammalian genomes have 5 lysyl oxidase gene family members, including the prototypic LOX and LOX-like proteins 1 through 4, all of which have highly similar catalytic domains. We describe here variants in one of the lysyl oxidase genes, LOX, that disrupt enzyme function and predispose to TAAD.
Methods
Exome sequencing was used to identify the mutation responsible for a large family with TAAD. Sanger and exome sequencing was performed to investigate rare variants in candidate genes in an additional 410 probands from unrelated families and tested the segregation of these variants with aortic diseases in families. Expression of the LOX variants and lysyl oxidase activities were measured to investigate biological function of rare LOX variants. An expanded Methods section is available in the Online Data Supplement.
Family Recruitment and Characterization
Blood or saliva samples were collected from affected individuals and family members after obtaining informed consent and approval from all participating institutions, including the University of Texas Health Science Center at Houston, Cleveland Clinic, and the Center de Reference pour les Syndromes de Marfan et Apparentés in France. Medical records, including imaging studies of the aorta, surgical reports, hospital records, death certificates, and physicians' notes, were reviewed.
Results

Identification of LOX Rare Variants Associated With FTAAD
To identify additional novel genes that cause an inherited predisposition to TAAD, exome sequencing was pursued using DNA from 3 affected individuals from family TAA602 with autosomal dominant inheritance of thoracic aortic disease, but no mutations in the known TAAD genes were identified ( Figure 1A) . 8 Gene variants identified by whole-exome sequencing were filtered based on the following: (1) variants that altered the amino acid sequence of proteins, including nonsynonymous, stop-lost, stop-gain, coding indels, frameshift, or splice site variants; (2) variants that had minor allele frequency of <0.05% in the National Heart, Lung, and Blood Institute Exome Sequencing Project (ESP) database; and (3) variants shared between the 3 affected relatives. 9 The variants that met these criteria were assessed for segregation with aortic disease in TAA602, decreasing the number of genes with candidate rare variants down to 10 (Online Table I ). Among these genes, LOX (NM_002317.5) was the best candidate gene for causing aortic disease because of the established role of lysyl oxidases in connective tissue mechanical stability, the relatively high expression in SMCs, and the fact that Lox −/− mice die of thoracic aortic rupture shortly after birth. 12 The LOX variant identified in TAA602, p.Ser280Arg, falls in the catalytic domain of the enzyme and is predicted to be damaging by 5 of 7 functional prediction programs. The C score of combined annotation-dependent depletion prediction (http:// cadd.gs.washington.edu/score) is 17.36. This variant is absent in 13 000 chromosomes in the ESP database and only present in 2 of 121 214 chromosomes (minor allele frequency of 1.65×10 -5 ) in the Exome Aggregation Consortium database. In addition, serine 280 and its flanking amino acids are highly conserved from human through zebrafish ( Figure 1B ).
Exome and Sanger sequencing of an additional 410 unrelated FTAAD probands identified 5 additional LOX rare variants that disrupted the protein sequence: c.125G>A (p.Trp42*), c.604G>T (p.Gly202*), c.743C>T (p.Thr248Ile), c.800A>C (p.Gln267Pro), c.1044T>A (p.Ser348Arg), c.235G>A (p.Ala79Thr), and c.460C>T (p.Leu154Phe). The nonsense variant p.Trp42* identified in TAA-92291 is predicted to lead to nonsense-mediated decay and cosegregated with thoracic aortic aneurysms in the family. The p.Gly202* variant identified in TAA271 is predicted to lead to nonsense-mediated decay. This LOX variant is not present in the proband's unaffected mother; however, samples from the affected father and uncle were not available. Notably, no LOX nonsense or indel variants are found in the ESP database and only 1 frameshift variant is found in 121 182 chromosomes in the Exome Aggregation Consortium database. Variants, p.Thr248Ile, p.Gln267Pro, and p.Ser348Arg, are absent in the ESP and Exome Aggregation Consortium databases, are predicted to be damaging or deleterious by >4 of 7 programs, have C scores of 11.7, 28.0, and 24.7, respectively, and are located in the highly conserved catalytic domain of the protein. Glutamine 267, serine 280, and serine 348 are conserved from human through zebrafish, and the amino acid at position 248 is threonine or serine among these species ( Figure 1B and  1C) . The ESP database has only 1 nonsynonymous rare variant in European Americans, p.Lys320Glu, in the LOX catalytic domain. Additional samples were not available from other affected members of TAA111 and TAA703. The last 2 rare variants identified disrupt Ala79 and Leu154; both of which are located in the propeptide region of LOX, and this region is removed after post-translational procedure. This region of LOX contains multiple rare variants in the general population, and LOX p.Ala79Thr and p.Leu154Phe are predicted to be benign or neutral by 6 of 7 programs and are not conserved ( Figure 1C ; Table) . Thus, these LOX rare variants are likely benign. In addition, LOX p.Ala79Thr was identified in a family with a disease-causing ACTA2 mutation. Therefore, we determined that possible disease-causing LOX variants are responsible for ≈1% of familial thoracic aortic disease and associated with decreased penetrance.
Clinical Characterization of Affected Individuals With LOX Rare Variants
The proband of family TAA602 is a 37-year-old European American woman with fusiform dilatation of the aortic root and ascending aorta, measuring 3.8 cm and 4.1 cm, respectively. Mild mitral regurgitation was also noted, and her physical examination was negative for syndromic features. Her father was 62 years old when he was diagnosed with a 5.2-cm aortic root aneurysm that involved the ascending aorta (4.2 cm) and aortic arch (4.0 cm). He also has a bicuspid aortic valve, a 3-vessel coronary artery disease and severe left ventricular hypertrophy. He underwent an aortic valve replacement and root and ascending aorta replacement, along with a coronary artery bypass graft. The proband's paternal uncle had an ascending aortic dissection at the age of 60 years. A paternal aunt was diagnosed with a 3.9-cm aortic root aneurysm and an ectatic ascending aorta at the age of 54 years. The proband of family TAA111 is a European American man who had an incidental finding of a 12.5-cm ascending aortic aneurysm and underwent an aortic valve replacement and ascending aortic replacement at the age of 41 years and aortic root aneurysm repair at the age of 51 years. His father died suddenly at the age of 56 years. The proband of family TAA271 is a 36-year-old European American man with an unremarkable physical examination, who was diagnosed with a 4.2-cm aortic root with fusiform enlargement of the ascending aorta. Because of the dissection deaths of his father and paternal uncle, he underwent an elective aortic root and ascending aorta replacement and aortic valve repair. The proband of TAA703 is a European American women, who was diagnosed with a-5.2 cm ascending aortic aneurysm and transverse aortic arch aneurysm and bicuspid aortic valve at the age of 40 years. She has no features of a genetic syndrome. Her father died at the age of 53 years because of a ruptured ascending aorta. The proband of TAA-92291 underwent surgery for a thoracic aortic aneurysm at the age of 11 years and has additional Marfan-like features, including dolichostenomelia, scoliosis, and pectus excavatum. Three of the proband's relatives with the LOX variant (II:3, II:4, and III:1) underwent thoracic aortic aneurysm repair at 70, 72, and 59 years old, respectively. Individual II:1 died at the age of 70 years after thoracic aortic surgery, and individual III:2 has a thoracic aortic aneurysm requiring surgery; DNA samples from these individuals were not available. Limited clinical information was available for this family. The proband of TAA-9544 had a bicuspid aortic valve and thoracic aortic aneurysm and underwent a Bentall procedure at the age of 16 years. He also has features of Marfan syndrome, including a highly arched palate, joint laxity, and skin striae. A maternal uncle (II:1), who underwent a composite graft repair of a thoracic aneurysm at the age of 51 years, along with a first cousin (III:3) and first cousin once removed (IV:1), both with aortic root enlargement, also carry the LOX variant. DNA samples were not available from the proband's maternal grandparents, but the grandfather had a thoracic aortic surgery at the age of 54 years. Dural ectasia, pectus deformity, joint hypermobility, and skin striae were variably present in the family members.
The aortic pathology in 2 patients, the proband's father in TAA602 (II:5) with p.Ser280Arg and the proband in TAA271 (III:4) with p.Gly202*, both of whom underwent prophylactic repair of thoracic aortic aneurysms, was assessed. The control aorta shows the orderly structure of the alternating layers of wavy elastic fibers (black) and SMCs (Figure 2 , red). The aortas from both patients with LOX variants showed mild medial degeneration characterized by focal loss of elastin fibers and SMCs but limited deposition of proteoglycans (Figure 2 , top). Perhaps a more significant finding in the patients' aortic pathology is the disorganization of the elastic fiber deposition when compared with the control aorta (Figure 2, middle) . In addition, collagen deposition may be increased in the patients' aortas (Figure 2 , bottom).
LOX Missense Variants in the Enzymatic Domain Decrease LOX Activity
The protein product of LOX (referred to as LOX) is synthesized as a 50-kDa inactive proenzyme (pro-LOX) that subsequently undergoes N-and O-glycosylation at sites in the propeptide domain, and then it is secreted from the cells and cleaved extracellularly to form the functional C-terminal 30-kDa enzyme and 18-kDa N-terminal propeptide fragment ( Figure 1C ). Recombinant plasmids were constructed to express either the wild-type (WT) LOX or each of the mutant LOX proteins (Thr248Ile, Ser280Arg, and Ser348Arg) with either a human influenza hemagglutinin or FLAG tag (DYKDDDDK) at the C-terminus. The plasmids were transfected individually into HeLa cells, and immunoblot analyses using antibodies against either LOX or the protein tags showed similar levels of the pro-LOX protein for all 4 constructs ( Figure 3A) . At the same time, immunoblot analysis using the LOX antibody showed that the levels of active mutant LOX (molecular weight, 34 kDa) were lower than those of the WT, with the Thr248Ile mutation 4% lower, the Ser280Arg 27% lower, and the Ser348Arg 14% lower ( Figure 3A) . Surprisingly, the antibodies directed against either the FLAG or hemagglutinin tag failed to recognize the active protein. Lysyl oxidase activity was assayed at 5 time points by spectrophotometric detection of the byproduct of LOX enzymatic activity, hydrogen peroxide, and the enzymatic activity corrected for the decreased protein levels of the active LOX mutants relative to the WT level. The mutant LOX constructs, Thr248Ile, Ser280Arg, and Ser348Arg, had lysyl oxidase activity levels that were 92%, 50%, and 79% of that of WT LOX, respectively (P=0.03 to 5.2×10 -8 ; Figure 3B ). 
Discussion
The data presented here support the conclusion that heterozygous loss-of-function mutations in LOX, specifically variants that disrupt the catalytic activity or lead to haploinsufficiency, predispose to thoracic aortic aneurysms and acute aortic dissections. Overlapping syndromic features of Marfan syndrome, such as pectus deformities and striae, were reported in family members with LOX variants, but these features were not sufficient to meet diagnostic criteria for Marfan syndrome. 13 Thoracic aortic aneurysms in these individuals are either aortic root aneurysms or fusiform aneurysms, involving both the aortic root and ascending aorta. Although mutation carriers died of ascending aortic dissections, there were no reports of aortic dissections with minimal enlargement of the ascending aorta. None of the affected individuals presented with descending thoracic aortic aneurysms or dissections. Interestingly, a bicuspid aortic valve was identified in 3 of 18 individuals with LOX mutations. It is also notable that probands from 2 families, TAA-92291 and TAA-9544, underwent thoracic aortic aneurysm repair at the age of 11 and 16 years, respectively, therefore presented much younger than their affected family members and other LOX mutation carriers. This young age of onset could be because of environmental modifiers of the phenotype but is perhaps more likely due to a second genetic alteration leading to an early onset of the disease.
Lysyl oxidases are extracellular copper enzymes that initiate the formation of lysine-derived cross-links in elastin and collagen. There are 5 lysyl oxidase gene family members with highly similar catalytic domains. The specific function of some of these genes has been determined through deletion of these genes in mice. Lox −/− mice die at the end of gestation or soon after parturition because of aortic rupture with evidence of aortic aneurysms and aortic tortuosity. 11, 12 Importantly, 80% of lysyl oxidase activity is lost with deletion of Lox, suggesting that LOX encodes the majority of the lysyl oxidase in the aorta.
14 Electron microscopic examination of Lox −/− mouse aortas shows a decreased amount and fragmentation of the elastic laminae, along with marked disorganization of the elastin fibers, similar to what was observed in the aortic pathology associated with LOX mutations (Figure 2) . Thus, other lysyl oxidase genes cannot compensate for the loss of Lox in aortas of mice to assure proper development of the aorta. In contrast, deletion of Loxl1 does not disrupt aortic development in mice but instead leads to uterine and bowel prolapse and enlarged airspaces in the lung. 15 The loss of lysyl oxidase activity because of the LOX mutations may predispose to thoracic aortic disease through aberrant development of the thoracic aorta because of fewer elastin cross links, leading to decreased and fragmented elastic fiber as observed in the Lox −/− mice. It is also established that irreversible inhibition of lysyl oxidase activity by administration of β-aminopropionitrile induces Thoracic aortic aneurysms in both young turkeys and rats. [16] [17] [18] [19] [20] [21] The aortic pathology in β-aminopropionitrile-treated young rats shows features of medial degeneration, including elastin degradation, thickening of the medial layer, and SMC apoptosis. 22 Thus, inhibition of lysyl oxidase activity also induces thoracic aortic disease postnatally. Because elastin layers are laid down during development, it raises the possibility that the stability of the aorta provided by lysyl oxidase activity may result from the crosslinking of collagen, which has a relatively short half-life in the aorta in comparison with elastin.
Although LOX mutations have not been described in humans until this report, secondary lysyl oxidase deficiency can occur in individuals with Menkes syndrome and the less severe occipital horn syndrome. Mutations in ATP7A, a copper transporter necessary for copper absorption, cause both Menkes syndrome and occipital horn syndrome, and loss of copper leads to reduced activities of copper-dependent enzymes, including all lysyl oxidases. 23 Vascular abnormalities, such as vascular tortuosity and arterial aneurysms, have been observed in individuals with Menkes syndrome and occipital horn syndrome and are associated with fragmentation and disruption of the elastic lamellae. Furthermore, a mouse model of Menkes syndrome develops aneurysms in the ascending, descending thoracic, and abdominal aortas within the age of 6 months. 24 The overlap of the aortic disease in Menkes syndrome with the phenotype of FTAAD because of LOX mutations provides further evidence that lysyl oxidase activity is important for maintaining structural integrity of the aorta throughout a lifetime. The rare variants in FTAAD that were classified as disease causing fall in the catalytic domain, which is relatively invariant in the general population. Lysyl oxidase activity is predicted to be decreased by 50% with the decrease by p.Trp42* and p.Gly202*, and we found that the other rare variants, p.Thr248Ile, p.Ser280Arg, and p.Ser348Arg, decrease activity from 50% to 92% of that of the WT allele. Thus, with the addition of the WT allele, total LOX activity is predicted to be 75% to 96% of that of normal, raising the question why the relatively modest decrease in enzymatic activity would cause thoracic aortic disease. One possibility is that the active mutant protein is less stable than the active WT protein. We found that all the mutations lead to decrease active LOX protein levels when the proteins were overexpressed in HeLa cells, supporting this possibility. In addition, although we have focused on disruption of the catalytic activity by the rare variants associated with TAAD, it is important to note that LOX has other functions in the cell. The LOX propeptide region targets LOX to elastin fibers in the extracellular matrix by mediating its interactions with tropoelastin. 25 LOX is also reported to localize the nucleus in SMCs, where data indicate that it has a role in chromatin structure regulation and gene transcription. 26, 27 Thus, the LOX rare variants identified associated with FTAAD may disrupt other functions of the protein than just the catalytic activity. Finally, it is important to note that we were not able to confirm that the LOX variant that disrupted protein stability and activity minimally, p.Thr248Ile, segregated with disease in the family. Therefore, this variant may not be disease causing.
In summary, accumulating evidence indicates that the loss of lysyl oxidase activity because of mutations in LOX predisposes individuals to fusiform thoracic aortic aneurysms and ascending aortic dissections. Bicuspid aortic valve was present in 3 of the 20 carriers of LOX mutations. Normal heart valves develop from cardiac cushions, which undergo extensive remodeling that involves cell differentiation, apoptosis, and remodeling of extracellular matrix. Thus, defects in LOX function have the potential to contribute to this congenital valve abnormality and thoracic aortic disease. Additional studies are needed to define the spectrum of mutations and further delineate the clinical phenotype. 
Materials and Methods
Exome and Sanger Sequencing
Genomic DNA was extracted from peripheral blood lymphocytes using standard protocols.
Five micrograms of DNA from three affected individuals in family TAA602 were used for construction of the shotgun sequencing library as described previously using adaptors for pairedend sequencing. Exome sequences were captured by SeqCap EZ. Exome probes version 2.0 (Roche) and recovered according to manufacturer's directions. Enriched libraries were then sequenced on an Illumina GAIIx using manufacturer protocols. Reads were mapped to the reference human genome (UCSC hg19) with BWA (Burrows-Wheeler Aligner), and variant detection and genotyping are performed using the UnifiedGenotyper (UG) tool from GATK. 
Construction of LOX recombinant plasmids:
WT-LOX was amplified by using pcDNA-LOX (GenScript, Inc., Piscataway Township, NJ) with Lysates (20 ug) were separated by 4-15% SDS polyacrylamide gel electrophoresis (TGX Mini Protean, Bio-Rad) with Tris-glycine running buffer. The proteins were transferred to a nitrocellulose membrane using the iBlot dry blotting system (Life Technologies). The membrane was blocked with 5% skim milk and incubated with rabbit polyclonal primary anti-LOX diluted 1:1,000 (abcam). The membrane was also incubated with rabbit monoclonal anti-GAPDH (1:5,000)
to confirm equal loading of cellular proteins. The immune complexes were visualized using enhanced chemiluminescence reagent (Western Lightning Chemiluminescence ECL Pro, Perkin
Elmer, Waltham, MA) and detected with ImageQuant LAS4000 (GE Healthcare).
Pathology Analysis
Aorta from patients and healthy control were sectioned and stained with Movat pentachrome and picro sirius red. 
